Brief: Acerus announces NATESTO license agreement with Hyundai Pharm
15/12/2016 22:30
Dec 15 (Reuters) - Acerus Pharmaceuticals Corporation
ASP.TO :
* Acerus pharmaceuticals corporation- acerus is eligible to
receive a milestone payment upon regulatory approval of natesto
in south korea
* Acerus pharmaceuticals corporation - will receive
non-refundable upfront fee, with a first instalment paid at
signing and remaining payable in jan 2017
* Acerus pharmaceuticals corporation- acerus will oversee
manufacturing of natesto and receive a supply price for product
* Press release - acerus announces natesto license
agreement with hyundai pharm
Source text for Eikon: urn:newsml:reuters.com:*:nBw82p6B0a
Further company coverage: ASP.TO
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Hyundai Pharmaceutical
See all newsS.Korea morning-after pill makers jump as court strikes down abortion law
S.Korean stocks close little changed; won edges lower
Brief: Acerus Pharmaceuticals Announces Approval Of Natesto In South Korea
Brief: Mithra Pharmaceuticals To Commercialise Estelle In South Korea With Hyundai Pharm
Brief: Hyundai Pharmaceutical to pay annual cash dividend as 50 won/share